Skip to content

Our pipeline

We are building a strong and diversified, late-stage proprietary pipeline of innovative, single-pill combination therapies in novel and unique dosage strengths, targeting some of the leading causes of death in both developed and developing countries, including hypertension, cardiovascular disease and type 2 diabetes. Our most advanced candidate, GMRx2, is a single-pill, triple-combination, in novel and proprietary dosage strengths, for the first-line treatment of hypertension.

No.4 Fact

Our business model avoids the early, high-risk stages of drug discovery and development, reducing time-to-market, providing a higher probability of success and requiring less capital investment to bring our medicines to patients than is usual in the industry.

The overview

At George Medicines, we are focused on developing late-stage drugs to improve upon existing treatments of non-communicable diseases through innovative, sustainable, and more patient-friendly methods.

Our innovative pipeline is targeting some of the world’s leading causes of death, including hypertension, atherosclerotic diseases and type 2 diabetes.

By developing best-in-class, existing treatments in innovative single-pill combinations, George Medicines is building a pipeline of future treatments with the potential to be more efficacious, safer, and more affordable than the current alternatives.

We understand the financial burden associated with current medications and the resultant impact on accessibility to regions worldwide. With all our combination therapies in development, accessibility is a core focus regardless of the region.

The George Medicines Pipeline

GMRx2
Phase III
Anticipated market launch
2023

GMRx2 is a single-pill, triple combination medicine containing telmisartan, amlodipine and indapamide, in novel and proprietary dosage strengths, in development as a first-line treatment for hypertension. Through this innovative combination we aim to tackle the growing issue of hypertension, one of the leading causes of cardiovascular disease and morbidity, while improving accessibility in key markets across the globe1,2. GMRx2 has the potential to provide an optimal balance of reduced side effects compared with current treatments, while increasing both efficacy and patient adherence to the therapy, potentially aiding millions globally.

In the US less than half of those treated for hypertension achieve adequate blood pressure control3.

GMRx2, in low- and ultra-low-dose formulations, aims to:

  • Reduce blood pressure to adequate blood pressure levels4
  • Reduce the likelihood of side effects compared to currently prescribed doses5
  • Increase adherence due the reduction in number of pills

GMRx1
Phase III Ready
Anticipated market launch
2023/24

GMRx1 is a four drug, single-pill combination for the treatment of people who have had a heart attack, stroke or other type of cardiovascular disease (CVD). The George Institute for Global Health has been a leader in the development and trialling of these potential medicines, which aim to provide an essential vascular care package to people at highest risk of recurrent CVD events.


GMRx3 & GMRx4
In development
Anticipated market launch
2025

GMRx3 and GMRx4 are single-pill, triple combinations of low-dose blood glucose lowering medicines, being investigated as treatments for those with type 2 diabetes, which accounts for around 90% of those diagnosed with diabetes mellitus. Worldwide, approximately 460 million adults are living with diabetes, which is expected to grow to 700 million by 2045. Type 2 diabetes is characterised by insulin resistance where the body does not fully respond to insulin, resulting in the rise of blood glucose and further rise in insulin release. This process can exhaust the pancreas resulting in reduced insulin production causing higher blood sugar levels. With GMRx3 and GMRx4, we aim to reduce blood glucose levels while reducing the number of medicines required with current treatments.


References

1Murray CJL, Aravkin AY, Zheng P, Abbafati C, Abbas KM, Abbasi-Kangevari M, et al. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 2020;396(10258):1223-49.
2The Blood Pressure Lowering Treatment Trialists’ Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. The Lancet. 2021;397(10285):1625-36.
3Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310(9):959-68.
4Fryar CD, Ostchega Y, Hales CM, Zhang G, Kruszon-Moran D. Hypertension prevalence and control among adults: United States, 2015–2016.
5Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018:ehy339-ehy.